<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870541</url>
  </required_header>
  <id_info>
    <org_study_id>HDF15891</org_study_id>
    <nct_id>NCT04870541</nct_id>
  </id_info>
  <brief_title>Nefopam Versus Ondansteron for Prevention of Post Spinal Shivering.</brief_title>
  <official_title>Comparative Study Between Nefopam and Ondansteron for Prevention of Post Spinal Shivering. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint-Joseph University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint-Joseph University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal anesthesia affects the homeostatic systems resulting in intraoperative hypothermia and&#xD;
      subsequently shivering. In fact, shivering may be seen after this technique in 30 to 40% of&#xD;
      cases . Ondansetron and Nefopam have been used to prevent intraoperative shivering . However,&#xD;
      no prospective, randomized, double-blind study has been conducted to this date in order to&#xD;
      compare nefopam with ondansetron in the prevention of post-spinal anesthesia shivering.&#xD;
&#xD;
      The primary objective of this prospective, randomized, double-blind study is to compare the&#xD;
      incidence and intensity of shivering after spinal anesthesia for non-obstetric surgery in 2&#xD;
      groups of patients.&#xD;
&#xD;
      Group A: Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over&#xD;
      30 minutes as they arrive to the operating theater(75 patients).&#xD;
&#xD;
      â€¢ Group B: Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30&#xD;
      minutes as they arrive to the operating theater (75 patients)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of shivering</measure>
    <time_frame>Shivering score was noted every 15 minutes from drug administration up to 120 minutes.</time_frame>
    <description>Number of episodes of shivering and variation will be noted every 15 minutes from drug administration up to 120 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of shivering</measure>
    <time_frame>Shivering score was noted every 15 minutes from drug administration up to 120 minutes.</time_frame>
    <description>Grades of shivering will be noted every 15 minutes from drug administration up to 120 minutes. Shivering will be graded : 0 = no shivering, 1= piloerection or peripheral vasoconstriction but no visible shivering, 2 = muscular activity in only one muscle group, 3 = muscular activity in more than one muscle group but not generalized shivering, 4 = shivering involving the whole body.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea/Vomitting</measure>
    <time_frame>Every 15 minutes from drug administration up to 120 minutes</time_frame>
    <description>Number of episodes of nausea and/or vomiting during and after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotention/Bradycardia</measure>
    <time_frame>Every three minutes from drug administration up to 120 minutes.</time_frame>
    <description>Hypotention: Number of episodes of hypotension SBP &lt;90mmhg or &lt;25% of baseline SBP in post spinal anesthesia until discharge from the PACU.&#xD;
Bradycardia: Number of episodes of bradycardia &lt;50 / min post-spinal anesthesia until discharge from the PACU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on injection site by analogue visual scale.</measure>
    <time_frame>During administration of drug.</time_frame>
    <description>Pain upon administration of drug on site of injection will be assessed using the analogue visual scale .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Shivering</condition>
  <condition>Adverse Effects in the Therapeutic Use of Anaesthetic</condition>
  <arm_group>
    <arm_group_label>Patients receiving Ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients receiving Nefopam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 8mg</intervention_name>
    <description>Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).</description>
    <arm_group_label>Patients receiving Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nefopam Injectable Solution</intervention_name>
    <description>Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)</description>
    <arm_group_label>Patients receiving Nefopam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 65 years&#xD;
&#xD;
          -  scheduled for a surgery under spinal anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breastfeeding (for the women), if they are&#xD;
&#xD;
          -  Allergy to any of the drugs to be used&#xD;
&#xD;
          -  Long QT syndrome&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Parkinson's disease&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Phenylketonuria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine Dagher, MD</last_name>
    <phone>+9613477332</phone>
    <email>chdagher@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universite Saint Joseph , Hotel Dieu de France</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Dagher, MD</last_name>
      <phone>+9613477332</phone>
      <email>chdagher@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <reference>
    <citation>Kang P, Park SK, Yoo S, Hur M, Kim WH, Kim JT, Bahk JH. Comparative effectiveness of pharmacologic interventions to prevent shivering after surgery: a network meta-analysis. Minerva Anestesiol. 2019 Jan;85(1):60-70. doi: 10.23736/S0375-9393.18.12813-6. Epub 2018 Sep 18. Review.</citation>
    <PMID>30226340</PMID>
  </reference>
  <reference>
    <citation>Crowley LJ, Buggy DJ. Shivering and neuraxial anesthesia. Reg Anesth Pain Med. 2008 May-Jun;33(3):241-52. doi: 10.1016/j.rapm.2007.11.006. Review.</citation>
    <PMID>18433676</PMID>
  </reference>
  <reference>
    <citation>Mathews S, Al Mulla A, Varghese PK, Radim K, Mumtaz S. Postanaesthetic shivering--a new look at tramadol. Anaesthesia. 2002 Apr;57(4):394-8.</citation>
    <PMID>11949644</PMID>
  </reference>
  <reference>
    <citation>Lv M, Wang X, Qu W, Liu M, Wang Y. Nefopam for the prevention of perioperative shivering: a meta-analysis of randomized controlled trials. BMC Anesthesiol. 2015 Jun 9;15:87. doi: 10.1186/s12871-015-0068-y.</citation>
    <PMID>26055978</PMID>
  </reference>
  <reference>
    <citation>Rai S, Verma S, Pandey HP, Yadav P, Patel A. Role of butorphanol and ondansetron premedication in reducing postoperative shivering after general and spinal anesthesia: A randomized comparative study from North India. Anesth Essays Res. 2016 May-Aug;10(2):319-23. doi: 10.4103/0259-1162.172724.</citation>
    <PMID>27212768</PMID>
  </reference>
  <reference>
    <citation>Marashi SM, Soltani-Omid S, Soltani Mohammadi S, Aghajani Y, Movafegh A. Comparing Two Different Doses of Intravenous Ondansetron With Placebo on Attenuation of Spinal-induced Hypotension and Shivering. Anesth Pain Med. 2014 Mar 18;4(2):e12055. doi: 10.5812/aapm.12055. eCollection 2014 May.</citation>
    <PMID>24790900</PMID>
  </reference>
  <reference>
    <citation>Tsai YC, Chu KS. A comparison of tramadol, amitriptyline, and meperidine for postepidural anesthetic shivering in parturients. Anesth Analg. 2001 Nov;93(5):1288-92.</citation>
    <PMID>11682416</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nefopam</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

